Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.11
ANGO's Cash to Debt is ranked lower than
52% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. ANGO: 0.11 )
ANGO' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.11

Equity to Asset 0.68
ANGO's Equity to Asset is ranked higher than
78% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. ANGO: 0.68 )
ANGO' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.94
Current: 0.68

0.06
0.94
Interest Coverage 3.68
ANGO's Interest Coverage is ranked higher than
51% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. ANGO: 3.68 )
ANGO' s 10-Year Interest Coverage Range
Min: 1.35   Max: 74.68
Current: 3.68

1.35
74.68
F-Score: 6
Z-Score: 2.29
M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 4.30
ANGO's Operating margin (%) is ranked higher than
68% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. ANGO: 4.30 )
ANGO' s 10-Year Operating margin (%) Range
Min: -10   Max: 13.14
Current: 4.3

-10
13.14
Net-margin (%) 1.11
ANGO's Net-margin (%) is ranked higher than
66% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.99 vs. ANGO: 1.11 )
ANGO' s 10-Year Net-margin (%) Range
Min: -8.13   Max: 8.75
Current: 1.11

-8.13
8.75
ROE (%) 0.75
ANGO's ROE (%) is ranked higher than
64% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. ANGO: 0.75 )
ANGO' s 10-Year ROE (%) Range
Min: -3.97   Max: 198.83
Current: 0.75

-3.97
198.83
ROA (%) 0.50
ANGO's ROA (%) is ranked higher than
65% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. ANGO: 0.50 )
ANGO' s 10-Year ROA (%) Range
Min: -3.51   Max: 9.77
Current: 0.5

-3.51
9.77
ROC (Joel Greenblatt) (%) 11.48
ANGO's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. ANGO: 11.48 )
ANGO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -26.38   Max: 43.53
Current: 11.48

-26.38
43.53
Revenue Growth (%) 5.20
ANGO's Revenue Growth (%) is ranked higher than
74% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. ANGO: 5.20 )
ANGO' s 10-Year Revenue Growth (%) Range
Min: 3.2   Max: 25.2
Current: 5.2

3.2
25.2
EBITDA Growth (%) 1.40
ANGO's EBITDA Growth (%) is ranked higher than
70% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. ANGO: 1.40 )
ANGO' s 10-Year EBITDA Growth (%) Range
Min: -33.8   Max: 31.3
Current: 1.4

-33.8
31.3
EPS Growth (%) -34.50
ANGO's EPS Growth (%) is ranked higher than
52% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. ANGO: -34.50 )
ANGO' s 10-Year EPS Growth (%) Range
Min: -34.5   Max: 100
Current: -34.5

-34.5
100
» ANGO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ANGO Guru Trades in Q4 2013

Steven Cohen 161,069 sh (New)
Jim Simons 186,046 sh (+100.65%)
Joel Greenblatt Sold Out
Mario Gabelli 105,000 sh (-4.55%)
Chuck Royce 812,776 sh (-15.19%)
» More
Q1 2014

ANGO Guru Trades in Q1 2014

Steven Cohen 380,250 sh (+136.08%)
Chuck Royce 772,576 sh (-4.95%)
Mario Gabelli 95,000 sh (-9.52%)
Jim Simons 67,546 sh (-63.69%)
» More
Q2 2014

ANGO Guru Trades in Q2 2014

Jim Simons 92,000 sh (+36.2%)
Chuck Royce 839,013 sh (+8.6%)
Steven Cohen 41,300 sh (unchged)
Mario Gabelli 86,000 sh (-9.47%)
» More
Q3 2014

ANGO Guru Trades in Q3 2014

Paul Tudor Jones 13,824 sh (New)
Jim Simons 153,160 sh (+66.48%)
Chuck Royce 848,531 sh (+1.13%)
Mario Gabelli 86,000 sh (unchged)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ANGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Sold Out 0.01%$13.38 - $16.71 $ 19.1825%0
Joel Greenblatt 2013-09-30 New Buy0.01%$10.9 - $13.55 $ 19.1863%16031
Mario Gabelli 2013-09-30 Reduce -24.14%$10.9 - $13.55 $ 19.1863%110000
Joel Greenblatt 2012-09-30 Sold Out 0.12%$10.41 - $12.66 $ 19.1868%0
Mario Gabelli 2012-09-30 Add 22.25%$10.41 - $12.66 $ 19.1868%165032
Joel Greenblatt 2012-03-31 Add 89.16%0.07%$12.22 - $14.63 $ 19.1859%140154
Joel Greenblatt 2011-09-30 Add 58.28%0.05%$12.81 - $15.44 $ 19.1838%63774
Mario Gabelli 2011-09-30 Reduce -49.13%0.01%$12.81 - $15.44 $ 19.1838%103000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 177.60
ANGO's P/E(ttm) is ranked higher than
67% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.00 vs. ANGO: 177.60 )
ANGO' s 10-Year P/E(ttm) Range
Min: 18.13   Max: 374.44
Current: 177.6

18.13
374.44
P/B 1.27
ANGO's P/B is ranked higher than
90% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. ANGO: 1.27 )
ANGO' s 10-Year P/B Range
Min: 0.64   Max: 6.67
Current: 1.27

0.64
6.67
P/S 1.91
ANGO's P/S is ranked higher than
79% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. ANGO: 1.91 )
ANGO' s 10-Year P/S Range
Min: 1.03   Max: 5.62
Current: 1.91

1.03
5.62
PFCF 83.39
ANGO's PFCF is ranked higher than
73% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 57.37 vs. ANGO: 83.39 )
ANGO' s 10-Year PFCF Range
Min: 8.87   Max: 285.43
Current: 83.39

8.87
285.43
EV-to-EBIT 52.56
ANGO's EV-to-EBIT is ranked higher than
69% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.42 vs. ANGO: 52.56 )
ANGO' s 10-Year EV-to-EBIT Range
Min: -570.9   Max: 181
Current: 52.56

-570.9
181
Shiller P/E 97.64
ANGO's Shiller P/E is ranked higher than
76% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 139.22 vs. ANGO: 97.64 )
ANGO' s 10-Year Shiller P/E Range
Min: 32.2   Max: 95.9
Current: 97.64

32.2
95.9
Current Ratio 2.42
ANGO's Current Ratio is ranked higher than
66% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. ANGO: 2.42 )
ANGO' s 10-Year Current Ratio Range
Min: 1.95   Max: 14.28
Current: 2.42

1.95
14.28
Quick Ratio 1.32
ANGO's Quick Ratio is ranked higher than
61% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. ANGO: 1.32 )
ANGO' s 10-Year Quick Ratio Range
Min: 1.16   Max: 12.12
Current: 1.32

1.16
12.12

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.14
ANGO's Price/DCF (Projected) is ranked higher than
93% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.64 vs. ANGO: 1.14 )
ANGO' s 10-Year Price/DCF (Projected) Range
Min: 0.54   Max: 1.09
Current: 1.14

0.54
1.09
Price/Median PS Value 1.06
ANGO's Price/Median PS Value is ranked higher than
79% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. ANGO: 1.06 )
ANGO' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 2.82
Current: 1.06

0.62
2.82
Earnings Yield (Greenblatt) 1.90
ANGO's Earnings Yield (Greenblatt) is ranked higher than
67% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. ANGO: 1.90 )
ANGO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 10.9
Current: 1.9

0.6
10.9
Forward Rate of Return (Yacktman) -7.17
ANGO's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.33 vs. ANGO: -7.17 )
ANGO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.8   Max: 6.6
Current: -7.17

-16.8
6.6

Analyst Estimate

May15 May16
Revenue(Mil) 367 389
EPS($) 0.57 0.70
EPS without NRI($) 0.57 0.70

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:UG2.Germany,
AngioDynamics Inc was incorporated in 1988 in Delaware. The Company designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company is organized in two segments: Vascular and Oncology/Surgery. The Oncology/Surgery Division includes Radiofrequency Ablation (RFA) and NanoKnife product lines. This division also includes the microwave ablation technology products obtained through the acquisition of Microsulis Medical Ltd. The Vascular division manages Fluid Management, Venous, AngioVac, Angiographic, PTA, Drainage, Thrombolytic, Micro Access Kits, Dialysis, PICC and Port product lines. The Company's product include the NAMIC Fluid Management portfolio. The NAMIC product line includes an extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers and interventional accessories. The devices are utilized together and allow clinicians to aspirate or inject contrast, saline, remove waste and monitor invasive blood pressures throughout the procedure. The venous products consist of our VenaCure EVLT laser system and Sotradecol. The AngioVac devices are for use with other manufacturer's off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of a extracorporeal bypass procedure for up to six hours. Thrombolytic catheters are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins and surgical bypass grafts. The micro access sets provide interventional physicians a smaller introducer system for minimally-invasive procedures. Image-guided vascular access, or IGVA, involves the use of advanced imaging equipment to guide the placement of catheters that deliver primarily short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system. Radiofrequency Ablation (RFA) products use radiofrequency energy to provide a minimally invasive approach to ablating solid cancerous or benign tumors. The NanoKnife Ablation System is for the surgical ablation of soft tissue. The NanoKnife Ablation System utilizes low energy direct current electrical pulses to permanently open pores in target cell membranes. The treated tissue is then removed by the body's natural processes in a matter of weeks, mimicking natural cell death. The Acculis Microwave Tissue Ablation (MTA) System complements the full range of ablative technologies. The Company competes with Boston Scientific Corporation; Cook Medical; Cordis Corporation, a subsidiary of Johnson & Johnson, Inc.; C.R. Bard; Medical Components, Inc., or Medcomp; Arrow International, a subsidiary of TeleFlex Medical; Smiths Medical, a subsidiary of Smiths Group PLC; Vascular Solutions; Covidien subsidiaries (Kendall, VNUS, EV3) and Merit Medical
» More Articles for ANGO

Headlines

Articles On GuruFocus.com
The Barclays Triggers More Insider Buying Mar 13 2013 
Weekly CEO Buys Highlight: JPM, ROG, PBY, ANGO, MCHX Jul 21 2012 
Weekly CEO Buys Highlight: WINA, ANGO, FES, LTS, TBOW Apr 15 2012 
Weekly CEO Buys Highlight: PKY, TWO, UVSP, AGYS, ANGO Feb 19 2012 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 07 2011 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Jan 08 2010 
AngioDynamics Inc. Reports Operating Results (10-Q) Oct 07 2009 
Weekly CEO Buys Highlight: CoBiz Financial Inc, Winmark Corp, The Greenbrier Companies Inc, AngioDyn Jul 26 2009 
Weekly CEO Buys Highlight: The Greenbrier Companies, AngioDynamics, Hallmark Financial Services, Ves Apr 18 2009 


More From Other Websites
AngioDynamics to Report Fiscal 2015 Second Quarter Financial Results Dec 17 2014
AngioDynamics to Report Fiscal 2015 Second Quarter Financial Results Dec 17 2014
AngioDynamics (ANGO) Signs PICC Deal with HealthTrust Dec 11 2014
AngioDynamics Awarded HealthTrust PICC Contract Dec 09 2014
AngioDynamics Awarded HealthTrust PICC Contract Dec 09 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into... Dec 05 2014
AngioDynamics (ANGO) Stock: Moving Average Crossover Alert Nov 26 2014
AngioDynamics to Present at 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
AngioDynamics to Present at 26th Annual Piper Jaffray Healthcare Conference Nov 25 2014
Bull of the Day: AngioDynamics (ANGO) Nov 25 2014
ANGIODYNAMICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 18 2014
ANGIODYNAMICS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements... Nov 14 2014
AngioDynamics to Present at Upcoming Investor Conferences Nov 11 2014
AngioDynamics to Present at Upcoming Investor Conferences Nov 11 2014
Foundation Medicine Slumps: FMI Tumbles 9.6% in Session Nov 07 2014
ANGIODYNAMICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Oct 31 2014
NanoKnife System Receives OPS Procedure Classification Codes in Germany Oct 28 2014
Edwards Lifesciences (EW) Worth Watching: Stock Up 11% Oct 27 2014
RTI Surgical (RTIX) Jumps: Stock Moves 12.6% Higher Oct 24 2014
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into... Oct 23 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK